Delaware Chapter of the American College of Cardiology

Join us for the ACC Delaware Chapter Meeting: ACC by the Sea for engaging live education sessions from local, regional, and national experts with Q&A real-time. The educational meeting includes topics of cardio obstetrics, lipids, amyloid, etc., and a chapter update from our Governor Dr. Vinay Hosmane. Participation in this event will earn CME/CNE/and MOC. We look forward to seeing you (IN-PERSON) September 12 - 13, 2025!

For more Information and Register: Delaware ACC By the Sea: 2025 Chapter Meeting

Delaware Chapter of the American College of Cardiology

Our purpose is to contribute to the prevention of cardiovascular diseases, to ensure optimal quality of care for individuals with such diseases, and to foster the highest professional ethical standards. Please let us know what information you want to see here. Feel free to contact us with your ideas, needs and comments.

ACC Live Courses

For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings

Latest in Cardiology from ACC.org

ACC CardiaCast: GDMT Will Not Delay HF Treatment
In this episode, Michelle M. Kittleson, MD, PhD, FACC, and Estefania Oliveros Soles, MD, MSc, FACC discuss challenges in heart failure (HF) care, focusing on utilization of guideline-directed medical therapy (GDMT). Learners will hear tips on how to add and maximize GDMT in patients with HF.
ACC-Hosted UN Side Events Focus on Opportunities to Address Global Burden of NCDs
With the fourth High-level United Nations General Assembly (UNGA) meeting taking place in New York the week of Sept. 22, the ACC hosted two separate side events tied into the overall theme of "Equity and Integration: Transforming Lives and Livelihoods Through Leadership and Action on Noncommunicable Diseases (NCDs) and the Promotion of Mental Health and […]
New Global Burden of CVD Report Shows Wide Variation Among Countries
Cardiovascular disease remains the leading cause of disease burden, causing one in three deaths worldwide, according to the latest Global Burden of Disease study report published Sept. 24 in JACC and presented during a special side event as part of the 80th Session of the United Nations General Assembly in New York.
OASIS 4: Significant Weight Loss With Oral Semaglutide Comparable With High-Dose, SC Versions
Oral semaglutide 25 mg once daily was associated with significant weight loss vs. placebo, comparable with that seen with the 50 mg oral dose and with the subcutaneous (SC) injectable version of the drug, according to new results from the phase 3 OASIS 4 trial, published Sept. 17 in NEJM.
Metoprolol Versus Aficamten in Patients With Left Ventricular Outflow Tract Obstruction on Exercise Capacity in HCM
The MAPLE-HCM trial showed that, among patients with symptomatic obstructive HCM, aficamten monotherapy was superior to metoprolol monotherapy in improving peak oxygen uptake and hemodynamics, and decreasing symptoms.